Activity
-
Today we announced results from Q2 2024, a pivotal time for our team. Our key progress included the Phase 2a #obesity results demonstrating GSBR-1290…
Today we announced results from Q2 2024, a pivotal time for our team. Our key progress included the Phase 2a #obesity results demonstrating GSBR-1290…
Liked by Lei Shi
-
Really pleased to share the news that #AbbVie has licensed FutureGen Biopharmaceutical’s next-generation TL1A antibody for the treatment of…
Really pleased to share the news that #AbbVie has licensed FutureGen Biopharmaceutical’s next-generation TL1A antibody for the treatment of…
Liked by Lei Shi
-
I am honored to lead a multi-office team in representing Proteologix in its $850 million upfront sale to JNJ in record time! Congratulations to…
I am honored to lead a multi-office team in representing Proteologix in its $850 million upfront sale to JNJ in record time! Congratulations to…
Liked by Lei Shi
Publications
-
De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins.
J Mol Biol.
Filamentous phage was the first display platform employed to isolate antibodies in vitro and is still the most broadly used. The success of phage display is due to its robustness, ease of use, and comprehensive technology development, as well as a broad range of selection methods developed during the last two decades. We report here the first combinatorial synthetic Fab libraries displayed on pIX, a fusion partner different from the widely used pIII. The libraries were constructed on four V(L)…
Filamentous phage was the first display platform employed to isolate antibodies in vitro and is still the most broadly used. The success of phage display is due to its robustness, ease of use, and comprehensive technology development, as well as a broad range of selection methods developed during the last two decades. We report here the first combinatorial synthetic Fab libraries displayed on pIX, a fusion partner different from the widely used pIII. The libraries were constructed on four V(L) and three V(H) domains encoded by IGV and IGJ germ-line genes frequently used in human antibodies, which were diversified to mirror the variability observed in the germ-line genes and antibodies isolated from natural sources. Two sets of libraries were built, one with diversity focused on V(H) by keeping V(L) in the germ-line gene configuration and the other with diversity in both V domains. After selection on a diverse panel of proteins, numerous specific Fabs with affinities ranging from 0.2 nM to 20 nM were isolated. V(H) diversity was sufficient for isolating Fabs to most antigens, whereas variability in V(L) was required for isolation of antibodies to some targets. After the application of an integrated maturation process consisting of reshuffling V(L) diversity, the affinity of selected antibodies was improved up to 100-fold to the low picomolar range, suitable for in vivo studies. The results demonstrate the feasibility of displaying complex Fab libraries as pIX fusion proteins for antibody discovery and optimization and lay the foundation for studies on the structure-function relationships of antibodies.
Other authorsSee publication
Patents
-
Design and generation of human de novo pIX phage display libraries
US PCT/US2008/084255
-
Mannose Binding Lectin Knock-Out Mice and Methods of Use Thereof
US 7,491,868 B2
More activity by Lei
-
Proteologix, Inc. to be Acquired by Johnson & Johnson https://lnkd.in/gJa-pNUy I would like to thank Centerview Partners LLC as our exclusive…
Proteologix, Inc. to be Acquired by Johnson & Johnson https://lnkd.in/gJa-pNUy I would like to thank Centerview Partners LLC as our exclusive…
Liked by Lei Shi
-
Big thanks to all who joined our Lunch and Learn event with MassBio! Your engagement and insights made it a success. Special shoutout to our speakers…
Big thanks to all who joined our Lunch and Learn event with MassBio! Your engagement and insights made it a success. Special shoutout to our speakers…
Liked by Lei Shi
-
Catch us at the Festival of Biologics 2024! 👀 What are your thoughts on our presentation yesterday? 👨🏫 👩🏫 Leave some comments and let us…
Catch us at the Festival of Biologics 2024! 👀 What are your thoughts on our presentation yesterday? 👨🏫 👩🏫 Leave some comments and let us…
Liked by Lei Shi
-
Thanks to the hard work of our team and our partner, Kite & Gilead, we have reached another milestone! If you're interested in high-quality human…
Thanks to the hard work of our team and our partner, Kite & Gilead, we have reached another milestone! If you're interested in high-quality human…
Liked by Lei Shi
-
We are excited to welcome Janine Schuurman, co-inventor of the DuoBody®, HexaBody®, and HexElect® technologies—as well as many therapeutic…
We are excited to welcome Janine Schuurman, co-inventor of the DuoBody®, HexaBody®, and HexElect® technologies—as well as many therapeutic…
Liked by Lei Shi
-
Human Longevity has dedicated for over 10 years to deliver modern longevity cares to our customers. Health is the new wealth. By delaying major…
Human Longevity has dedicated for over 10 years to deliver modern longevity cares to our customers. Health is the new wealth. By delaying major…
Liked by Lei Shi
-
Such an important mission to help everyone around the world. Thanks Blai and everyone at Structure for all your doing to help address the obesity…
Such an important mission to help everyone around the world. Thanks Blai and everyone at Structure for all your doing to help address the obesity…
Liked by Lei Shi
-
Hello from Jeddah, Saudi Arabia!! My son Tom Rein and I are here for a couple of weeks to explore and learn about China's largest trade partner in…
Hello from Jeddah, Saudi Arabia!! My son Tom Rein and I are here for a couple of weeks to explore and learn about China's largest trade partner in…
Liked by Lei Shi
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More